Last reviewed · How we verify
NCT06609044: SAPIENCE2
Long-term Impact of NMDAR Encephalitis
trial in Autoimmune Encephalitis in 20 participants. Completed in 4 April 2025.
4 April 2025
Quick facts
| Lead sponsor | Hospices Civils de Lyon |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 16 December 2024 |
| Primary completion | 4 April 2025 |
| Estimated completion | 4 April 2025 |
| Sites | 1 location across France |
Conditions studied
- Autoimmune Encephalitis — all drugs for Autoimmune Encephalitis →
Sponsor
Hospices Civils de Lyon — full company profile →
Who can join
Adults 18 to 80, any sex, with Autoimmune Encephalitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
NMDA receptor antibody encephalitis is a rare autoimmune neurological disease of the central nervous system with an estimated incidence of 1.5 people per million per year. Patients with anti-NMDAR encephalitis experience an acute phase of the disease characterized by psychosis, memory loss, seizures, autonomic nervous system instability, or coma. Since the discovery of this disease 14 years ago by Prof. Dalmau, the clinical presentation of the acute phase has been well characterized, while the psychosocial impact of the disease remains largely unexplored. Currently, there are few cohort studies of patients that have identified persistent cognitive impairment as a factor impacting remission after the acute phase. Given the scarcity of information concerning the post-acute phase, it is therefore essential to determine the long-term social and psychological outcomes and their daily effects on the social and functional life of this severe disease. This is especially important as the patients are young, with a median age of 21 years, and may face lasting limitations potentially detrimental to their success in professional, educational, or social environments.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06609044
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Autoimmune Encephalitis
Currently open trials in the same condition.
- NCT07477015 — Study of Pathogenic Mechanisms and Identification of Novel Autoantibodies in Autoimmune Encephalitis · recruiting
- NCT06753955 — Phase 1 Study of ART5803 Safety and PK After IVIG in Healthy Participants · Phase 1 · active not recruiting
- NCT06575153 — Phase 1 Study of ART5803 in Healthy Participants · Phase 1 · active not recruiting
- NCT06079294 — Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism · NA · recruiting
- NCT06432803 — Metabolic Imaging for Diagnosis and Prognostication of Autoimmune encephalitiS · active not recruiting
Other Hospices Civils de Lyon trials
Trials by the same sponsor.
- NCT07569536 — Efficacy of the Alpha 2 Agonist Dexmedetomidine for Sympathetic Deactivation in REfractory Septic Shock · Phase 3 · not yet recruiting
- NCT07529314 — Evaluating Interventional Radiology for Cancer Pain Management · NA · not yet recruiting
- NCT07273929 — Comparative Study of the Effectiveness of Three Access Routes for Implanting an Electronic Intracardiac Device · Phase 3 · not yet recruiting
- NCT07474532 — Attitudes and Beliefs Related to Benzodiazepine Deprescribing · not yet recruiting
- NCT07313007 — Assessment of Gut Microbiota-Derived Amino Acid Metabolite Production in Patients With MASLD · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06609044 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospices Civils de Lyon
- Last refreshed: 23 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06609044.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing